COMMUNIQUÉS West-GlobeNewswire

Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection
17/12/2018
Press release Malmö, Sweden December 17, 2018 Acarix reports first patient enrollment in new clinical investigation exploring heart failure detection Acarix has initiated a new explorative clinical study to develop a [...]
Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2019.
17/12/2018
Latvia, 2018-12-17 13:34 CET (GLOBE NEWSWIRE) -- Latvijas Juras medicinas centrs JSC: Data of publication of financial reports in the year 2019: Consolidated not audited interim report for the 12 months of 2018 - 18.02. [...]
FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive Multiple Sclerosis
17/12/2018
U.S. Phase 2 Study to Begin in First Quarter of 2019 NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell [...]
ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
17/12/2018
TORONTO and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics [...]
TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology
17/12/2018
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) and Dana-Farber Cancer Institute today announced the publication of results from the multicenter Phase 1/1b trial of umbralisib (TGR-1202 [...]
Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
17/12/2018
DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. [...]
Dova Pharmaceuticals Announces Management Changes
17/12/2018
Dr. David Zaccardelli appointed President and Chief Executive Officer Jason Hoitt appointed Chief Commercial Officer Company provides preliminary estimates of fourth quarter net product sales of $2.4 to $2.7 million for [...]
Loop Industries Appoints Sidney Horn to Board of Directors
17/12/2018
MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (Nasdaq:Loop) (“Loop” or the “Company”), a leading technology innovator in sustainable plastic, announced today that its ‎Board of Directors has [...]
Voyager Therapeutics Joins Michael J. Fox Foundation Initiatives and Education Campaigns to Accelerate the Development of New therapies and a Cure for Parkinson’s Disease
17/12/2018
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today [...]
Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis
17/12/2018
BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company and the U.S. Food and Drug [...]
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
17/12/2018
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects Top-line data anticipated [...]
Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial
17/12/2018
PRESS RELEASE December 17, 2018 Saniona (OMX: SANION), a biotech company focused on CNS and eating disorders, today announced statistically and clinically significant weight loss for both doses of tesofensine compared [...]
FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
17/12/2018
Intended for U.S. Audience FDA approves Shire’s Motegrity ™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) Unlike other prescription CIC treatments, Motegrity [...]
Blood donors needed to help patients this holiday season
17/12/2018
OTTAWA, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services has called for more than 30,000 blood donors across the country to book and keep their appointments from Dec. 17 to Jan. 6, 2019 to ensure blood and [...]
Les donneurs de sang encouragés à prendre rendez-vous pour aider les patients pendant les Fêtes
17/12/2018
OTTAWA, 17 déc. 2018 (GLOBE NEWSWIRE) -- Ayant besoin de 30 000 donneurs d’ici le 6 janvier, la Société canadienne du sang demande aux gens d’aller donner du sang afin que les patients soignés dans les hôpitaux pendant [...]
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
17/12/2018
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced [...]
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
17/12/2018
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
17/12/2018
- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held [...]
TRU NIAGEN® Expands North American Footprint with Product Launch in Canada
17/12/2018
TRU NIAGEN® receives Natural Product Number from Health Canada and is approved for sale in the country to consumers and healthcare practitioners LOS ANGELES, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: [...]

Pages